Novartis AG (NVS)

75.90
0.50 0.66
NYSE : Health Technology
Prev Close 75.40
Open 75.79
Day Low/High 75.57 / 76.68
52 Wk Low/High 72.30 / 92.39
Volume 8.82M
Avg Volume 2.14M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 209.25B
EPS 5.50
P/E Ratio 15.23
Div & Yield 1.84 (2.21%)
17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

These 5 Health Care Stocks Are Breaking Out This Christmas

These 5 Health Care Stocks Are Breaking Out This Christmas

The health care sector has been a miserable performer lately -- but these five health trades are bucking the trend.

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

'Mad Money' Lightning Round: Kohlberg Kravis Roberts, Opko Health Are Worth It

Jim Cramer says he's still 'a believer' in KKR and Opko.

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Jim Cramer's 'Mad Money' Recap: Mild Pullback Means We Are Getting Back to Normal

Stocks kept rallying right through and after this rate hike, says Jim Cramer.

The Worst Biopharma CEOs of 2016 Are ...

The Worst Biopharma CEOs of 2016 Are ...

There was plenty of shame to spread around, but Theranos CEO Elizabeth Holmes' loathsome mix of arrogance, incompetence and duplicity makes her the Worst CEO of 2016.

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Ophthotech Plunges on Eye-Drug-Study Failure

Ophthotech Plunges on Eye-Drug-Study Failure

Fovista combined with the currently approved drug Lucentis failed to improve the vision of patients with wet, age-related macular degeneration compared to Lucentis alone.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats

Another day, another industry damaged by the president-elect's rhetoric. But these three companies are strong enough to overcome arm-twisting over drug prices.

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Dow Marches to Another Record Close as S&P 500, Nasdaq Also Rise

Stocks enjoyed another strong day on Wall Street as the financial sector pushed the S&P 500 higher.

Financials and Tech Shares Lift Wall Street; Dow Hits Record High

Financials and Tech Shares Lift Wall Street; Dow Hits Record High

The Dow trades at an all-time high Monday as the financial and energy sectors rise.

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting

I spent the weekend with thousands of blood disease researchers. This is what happened.

Dow Sets Record High as Oil Maintains Momentum

Dow Sets Record High as Oil Maintains Momentum

The Dow trades at an all time high Monday as crude oil climbs higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.

Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains

Stock Futures Rise as Wall Street Shrugs Off Italy Referendum Defeat; Oil Gains

Stock futures rise Monday as crude oil continues to climb higher and markets shrug off potential negative effects of Italy's 'no' vote on its constitutional reform referendum.

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out

Juno now finds itself one year, if not two years or more, behind rivals Novartis and Kite.

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

S&P 500, Dow and Nasdaq Post New Records as Crude Rallies

Wall Street scores a trifecta of record closes on Monday as a crude oil rally gives stocks an across-the-board boost.

Wall Street on Track for Across-the-Board Records as Crude Rallies

Wall Street on Track for Across-the-Board Records as Crude Rallies

Wall Street is on track for record closes for all the benchmark indices as crude oil resumes its rally.

Stocks Trade Near Records as Crude Oil Surge Plateaus

Stocks Trade Near Records as Crude Oil Surge Plateaus

Stocks are higher on Monday as an early-morning surge in crude oil prices plateaus around $47 a barrel.

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

Stocks Gain Steam as Oil Rises; Tyson Foods Shares Sink on Earnings

U.S. stocks rose early Monday as investors parsed comments from oil officials in Iran and Iraq, hinting at a production cut at next week's OPEC meeting.

Stock Futures Edge Higher as Crude Surges on Hopes for OPEC Deal

Stock Futures Edge Higher as Crude Surges on Hopes for OPEC Deal

Stock futures edge higher on Monday morning as investors pin hopes on a production freeze agreement among major oil producers.

European Stocks Recover Gains as Energy Companies Pull Markets Higher

European Stocks Recover Gains as Energy Companies Pull Markets Higher

European stocks turned positive amid bullish oil sentiment ahead of November 30 OPEC meeting.

Novartis In Talks to Buy Generic Drug Maker

Novartis In Talks to Buy Generic Drug Maker

Novartis is entering into talks to purchase Amneal Pharmaceuticals in a deal that could value the company at $8 billion.

'Mad Money' Lightning Round: Target, Amazon, Tesla

'Mad Money' Lightning Round: Target, Amazon, Tesla

Jim Cramer says take a pass on TGT and the dollar stores; look at AMZN instead.

Jim Cramer's 'Mad Money' Recap: Ahead of Veterans Day, Cautious Optimism for Growth

Jim Cramer's 'Mad Money' Recap: Ahead of Veterans Day, Cautious Optimism for Growth

Jim Cramer honors veterans and those willing to invest in a brighter future for America.

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Alexion Soars, Then Falls Amid Takeover Rumors

Alexion Soars, Then Falls Amid Takeover Rumors

The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.

Why Incyte's Shares Could Soon Hit $100

Why Incyte's Shares Could Soon Hit $100

The drug company reported strong earnings.

TheStreet Quant Rating: B (Buy)